All press releases
-
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany
-
Diaccurate introduces its world-leading Scientific Advisory Board
-
Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy
-
World Premiere: Diaccurate reveals the mechanism of immune disablement in HIV infection
-
Diaccurate appoints 4 world-class experts to head its scientific board